Body mass index and risk of breast cancer molecular subtypes in Korean women: a case-control study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jeong, Seok Hun | - |
dc.contributor.author | An, Yoonsuk | - |
dc.contributor.author | Ahn, Choonghyun | - |
dc.contributor.author | Park, Boyoung | - |
dc.contributor.author | Lee, Min Hyuk | - |
dc.contributor.author | Noh, Dong-Young | - |
dc.contributor.author | Park, Sue K. | - |
dc.date.accessioned | 2021-09-10T07:25:13Z | - |
dc.date.available | 2021-09-10T07:25:13Z | - |
dc.date.issued | 2020-01 | - |
dc.identifier.issn | 0167-6806 | - |
dc.identifier.issn | 1573-7217 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/19607 | - |
dc.description.abstract | Background Our main objective of this research was to analyze the effect of BMI on breast cancer risk according to various subtypes of breast cancer stratified with menopausal status. Methods By using a case-control study setting, we recruited a total of 16,190 female breast cancer patients aged between 35 and 80 years from 2003 to 2010. These breast cancer patients were then individually matched by age to control female group (1:2 ratios of cases and controls). Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated via multivariable logistic regression by setting normal BMI range (18.5-22.9) as the reference group. Results In premenopausal women, the risk of breast cancer of triple-negative subtype increased (OR 1.60, 95% CI 1.27-2.02) in obese II (BMI >= 30) women and in underweight women, it was Luminal A (OR 1.24, 95% CI 1.06-1.45) and HER2 express subtype (OR 1.43, 95% CI 1.26-1.62) that showed increased risk of breast cancer. In postmenopausal women, Luminal A (OR 2.35, 95% CI 2.01-2.75), Luminal B HER2 negative (OR 1.81, 95% CI 1.46-2.25) and triple-negative subtype (OR 2.25, 95% CI 1.85-2.72) showed higher risk of breast cancer in obese II women. Conclusion Our findings suggest that the effect of BMI on breast cancer differs according to various subtypes and hormone receptors and to menopausal status. | - |
dc.format.extent | 12 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Kluwer Academic Publishers | - |
dc.title | Body mass index and risk of breast cancer molecular subtypes in Korean women: a case-control study | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1007/s10549-019-05451-1 | - |
dc.identifier.scopusid | 2-s2.0-85076456041 | - |
dc.identifier.wosid | 000491396400001 | - |
dc.identifier.bibliographicCitation | Breast Cancer Research and Treatment, v.179, no.2, pp 459 - 470 | - |
dc.citation.title | Breast Cancer Research and Treatment | - |
dc.citation.volume | 179 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 459 | - |
dc.citation.endPage | 470 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | INTERNATIONAL EXPERT CONSENSUS | - |
dc.subject.keywordPlus | PRIMARY THERAPY | - |
dc.subject.keywordPlus | ESTROGEN | - |
dc.subject.keywordPlus | PREMENOPAUSAL | - |
dc.subject.keywordPlus | STATISTICS | - |
dc.subject.keywordPlus | HIGHLIGHTS | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordAuthor | Breast cancer | - |
dc.subject.keywordAuthor | Body mass index | - |
dc.subject.keywordAuthor | Obesity | - |
dc.subject.keywordAuthor | Molecular subtype | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.